机构：[1]Department of Transfusion, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072四川省人民医院[2]Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology and Visual Sciences Key Laboratory, Beijing 100730首都医科大学附属北京同仁医院首都医科大学附属同仁医院[3]Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan, Sichuan Academy of Medical Sciences andSichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, P.R. China四川省人民医院[4]Université Paris Cité, CNRS, Unité de Biologie Fonctionnelle et Adaptative, 75013 Paris, France[5]Department of Gastroenterology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610000[6]Department of Pharmacy, The Second Affiliated Hospital, Army Medical University, Chongqing 400000[7]Department of Clinical Nutrition, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, P.R. China四川省人民医院
U2 small nuclear RNA auxiliary factor 1 (U2AF1) is a multifunctional protein that plays a crucial role in the regulation of RNA splicing during eukaryotic gene expression. U2AF1 belongs to the SR family of splicing factors and is involved in the removal of introns from mRNAs and exon-exon binding. Mutations in U2AF1 are frequently observed in myelodysplastic syndrome, primary myelofibrosis, chronic myelomonocytic leukaemia, hairy cell leukaemia and other solid tumours, particularly in lung, pancreatic, and ovarian carcinomas. Therefore, targeting U2AF1 for therapeutic interventions may be a viable strategy for treating malignant diseases. In the present review, the pathogenic mechanisms associated with U2AF1 in different malignant diseases were summarized, and the potential of related targeting agents was discussed. Additionally, the feasibility of natural product-based therapies directed against U2AF1 was explored.
基金：
The present study was supported by the Young Scientists
Fund of the National Natural Science Foundation of China
(grant no. 82204858) and the Sichuan Science and Technology
Program (grant no. 2023NSFSC1761).
第一作者机构：[1]Department of Transfusion, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072
共同第一作者：
通讯作者：
通讯机构：[6]Department of Pharmacy, The Second Affiliated Hospital, Army Medical University, Chongqing 400000[7]Department of Clinical Nutrition, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, P.R. China[*1]Department of Pharmacy, The Second Affiliated Hospital, Army Medical University, 183 Xinqiao Road, Chongqing 400000, P.R. China[*2]Department of Clinical Nutrition, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, 32# W. Sec 2, 1st Ring Road, Qingyang, Chengdu, Sichuan 610072, P.R. China
推荐引用方式(GB/T 7714)：
Nian Qing,Li Yihui,Li Jingwei,et al.U2AF1 in various neoplastic diseases and relevant targeted therapies for malignant cancers with complex mutations (Review)[J].ONCOLOGY REPORTS.2024,51(1):doi:10.3892/or.2023.8664.
APA：
Nian Qing,Li Yihui,Li Jingwei,Zhao Liyun,Lima Fernando Rodrigues...&Ye Zhijun.(2024).U2AF1 in various neoplastic diseases and relevant targeted therapies for malignant cancers with complex mutations (Review).ONCOLOGY REPORTS,51,(1)
MLA：
Nian Qing,et al."U2AF1 in various neoplastic diseases and relevant targeted therapies for malignant cancers with complex mutations (Review)".ONCOLOGY REPORTS 51..1(2024)
